Topic: Life sciences and healthcare

Subscribe to Life sciences and healthcare RSS feed

Ontario Health Sector Payment Transparency Act, 2017 – Draft Regulation Published for Consultation

Jillian HyslopSara ZborovskiRandy SuttonBy Jillian Hyslop, Sara Zborovski and Randy Sutton on Posted in Life sciences and healthcare
As we reported, Ontario passed the Health Sector Payment Transparency Act, 2017 (Bill 160) in December 2017, which will require those defined as “payors” – such as pharmaceutical and medical device manufacturers, wholesalers and distributors – to disclose financial relationships with healthcare professionals and organizations to the government. On February 21, 2018, the Ontario Government … Continue reading

Ontario legislation requiring disclosure of payments to physicians receives Royal Assent

Ian TrimbleSara ZborovskiBy Ian Trimble and Sara Zborovski on Posted in Life sciences and healthcare, Pharmaceuticals and life sciences
On December 12, 2017, Bill 160 passed third reading and received Royal Assent.  Included in Bill 160 is the Health Sector Payment Transparency Act (the “Act”). This Act will come into force at a later date to be determined by the government. The stated purpose of the Act is to require the reporting of information … Continue reading

PAAB Announces New Code of Advertising Acceptance

Ian TrimbleSara ZborovskiBy Ian Trimble and Sara Zborovski on Posted in Life sciences and healthcare, Pharmaceuticals and life sciences
The Pharmaceutical Advertising Advisory Board (PAAB) has announced an updated Code of Advertising Acceptance (Code).  The new Code will be implemented beginning on January 1, 2018. The primary change is to the Code’s format.  It will only be available online and will allow keyword searching and filtering code provisions by core principle.  Other changes include … Continue reading

Federal Court upholds cancellation of reconsideration of Apotex’s ANDS for Apo-omeprazole

Jonathan ChongSara ZborovskiBrian R. DaleyBy Jonathan Chong, Sara Zborovski and Brian R. Daley on Posted in Life sciences and healthcare
The Federal Court dismissed Apotex’s application for judicial review of the Minister of Health’s withdrawal of a notice of compliance (NOC) granted to Apotex Inc. for Apo-omeprazole. Health Canada withdrew the NOC because Apotex had not demonstrated bioequivalence. Health Canada also rejected Apotex’s request for reconsideration. The court found Apotex did not have legitimate expectations … Continue reading

Ontario health sector disclosure legislation referred to committee

Ian TrimbleSara ZborovskiBy Ian Trimble and Sara Zborovski on Posted in Life sciences and healthcare, Pharmaceuticals and life sciences
As we reported, Ontario has introduced legislation that will require pharmaceutical and medical device manufacturers to disclose financial relationships with healthcare professionals and organizations to the government. The legislation has passed second reading and has been referred to committee.  The Standing Committee on General Government will hold public hearings on November 15, 16, 20, and … Continue reading

Ontario introduces legislation requiring disclosure of payments to physicians

Ian TrimbleSara ZborovskiBy Ian Trimble and Sara Zborovski on Posted in Life sciences and healthcare, Pharmaceuticals and life sciences
Following a consultation, legislation was introduced in the Ontario Legislature on September 27, 2017 that will require pharmaceutical and medical device manufacturers to disclose financial relationships to healthcare professionals and organizations. The Health Sector Payment Transparency Act is one of several acts introduced by Bill 160. It will require manufacturers to periodically disclose details about … Continue reading

Ontario considers requiring disclosure of drug company payments to healthcare providers

Ian TrimbleSara ZborovskiBy Ian Trimble and Sara Zborovski on Posted in Life sciences and healthcare, Pharmaceuticals and life sciences
The Government of Ontario has announced it is consulting with patients, healthcare providers, and the pharmaceutical and medical devices industries about current regulations and guidelines that govern the disclosure of payments from the private sector to healthcare professionals. Although some innovative pharmaceutical companies already voluntarily disclose payments to healthcare providers, Ontario is assessing what additional … Continue reading

FCA upholds Gilead victory invalidating Idenix patent relating to anti-HCV compounds

Adam HallerAmy GrenonJordana SanftBy Adam Haller, Amy Grenon and Jordana Sanft on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
In a brief decision, the Federal Court of Appeal dismissed Idenix’s appeal of a Federal Court decision which found that a patent owned by Idenix and purporting to claim anti-HCV compounds was invalid for: (i) failing to sufficiently disclose a synthetic method by which the claimed compounds could be made; and (ii) for lack of … Continue reading

Mid-year roundup – 2017

Jillian HyslopJordana SanftKristin WallBy Jillian Hyslop, Jordana Sanft and Kristin Wall on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
Hard to believe, but we are halfway through 2017 already! It has been a busy six months, with major developments, including Canada preparing to implement CETA and the Supreme Court of Canada abolishing the “Promise Doctrine.” Below, Pharma in Brief has compiled the top headlines so far this year. The Big Three: Utility and the … Continue reading

Sections of Vanessa’s Law regulating drugs for urgent public health need come into force

Sofia Lopez BancalariSara ZborovskiBy Sofia Lopez Bancalari and Sara Zborovski on Posted in Life sciences and healthcare, Pharmaceuticals and life sciences
On July 12, 2017, section 5 and subsections 6(3) and 6(4) of the Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law) came into force. These sections amend the Food and Drugs Act to require healthcare institutions to report serious adverse drug reactions and permit the Governor in Council to make regulations that specify what this … Continue reading

“Promise Doctrine” rejected as a basis for invalidating patents for lack of utility in landmark Supreme Court of Canada ruling

Christopher A. GuerreiroKristin WallJudith RobinsonBy Christopher A. Guerreiro, Kristin Wall and Judith Robinson on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
The “Promise Doctrine” has been conclusively rejected by Canada’s highest court as a basis for invalidating a Canadian patent. In a judgment that reverses years of jurisprudence in the lower courts, the Supreme Court of Canada today held that the level of utility required of a Canadian patent must not be measured by statements in … Continue reading

CETA tracker: CETA Bill C-30 receives royal assent to implement pharmaceutical patent reform

Chelsea NimmoKristin WallJudith RobinsonBy Chelsea Nimmo, Kristin Wall and Judith Robinson on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
It’s official – the Canadian government has approved the changes to Canada’s pharmaceutical patent regime. On May 16, 2017, Bill C-30 (the act intended to implement CETA into Canadian law) received royal assent, the final stage of the legislative process. Treaty/Act:        CETA/Bill C-30 (An Act to implement the Comprehensive Economic and Trade Agreement between Canada … Continue reading

Proposed regulations published on additional elements of Vanessa’s Law

Sara ZborovskiOlga FarmanBy Sara Zborovski and Olga Farman on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
On April 22, 2017, the Government of Canada published draft regulations Amending the Food and Drug Regulations (Vanessa’s Law) that provide details regarding the minister of health’s powers to require tests, assessments and studies of a drug post-market authorization. The draft regulations also set out additional reporting requirements for manufacturers based on the actions of … Continue reading

CETA tracker: patent term restoration is coming soon to Canada – what you need to know now

Kristin WallChelsea NimmoBy Kristin Wall and Chelsea Nimmo on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
Treaty/Act: CETA/Bill C-30 (An Act to implement the Comprehensive Economic and Trade Agreement between Canada and the European Union and its Member States and to provide for certain other measures) With Canada moving closer towards implementing the Comprehensive Economic and Trade Agreement (CETA), major reforms to Canada’s Patent Act are coming soon, including the availability … Continue reading

Supreme Court dismisses leave to appeal regarding test for obviousness-type double patenting in tadalafil s.6 case

Jordana SanftLouisa PontrelliBy Jordana Sanft and Louisa Pontrelli on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
Case: Apotex Inc v Eli Lilly Canada Inc, et al (SCC Docket 37368) Drug: CIALIS® (tadalafil) Nature of case: Application for leave to appeal decision upholding prohibition order granted pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 (the Regulations) Successful party: Eli Lilly Canada Inc. and ICOS Corporation (collectively Eli Lilly) Date of decision: April … Continue reading

Health Canada proposes regulations allowing importation of drugs not yet available in Canada for an urgent public health need

Sara ZborovskiBy Sara Zborovski on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
Health Canada has proposed regulations that will amend the Food and Drug Regulations to allow for importation of drugs that have not yet received regulatory approval from Health Canada. The new regulations will provide access to drugs that address an urgent public health need provided they have been approved in the United States, the European … Continue reading

Federal Court of Appeal revisits obviousness: guidance provided on “inventive concept” and “obvious to try” test

Judith RobinsonChristopher A. GuerreiroBy Judith Robinson and Christopher A. Guerreiro on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
Case: Bristol-Myers Squibb Canada Co v Teva Canada Limited, 2017 FCA 76 (A-191-16), aff’g (for different reasons) 2016 FC 580 (Court File No. T-1364-14) Drug: REYATAZ® (atazanavir bisulfate) Nature of case: Appeal from application for prohibition order granted pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 (the Regulations) Successful party: … Continue reading

FCA finds no failure to mitigate Apotex damages claim against Health Canada for delayed Apo-Trazodone NOC

Kristin WallBrian R. DaleyBy Kristin Wall and Brian R. Daley on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
Case: Apotex Inc v Her Majesty the Queen, 2017 FCA 73 (Court File No. A-553-14/A-554-14) Drug: Apo-Trazodone Nature of case: Appeal of action for damages in tort and breach of contract Successful party: Apotex Inc. (in part) Date of decision: April 6, 2017 Summary The Federal Court of Appeal allowed Apotex’s appeal, in part, from … Continue reading

Federal Court comments on the admissibility of ‘but for’ world s. 8 evidence and rejects generic pipefill claim

Allyson Whyte NowakAmy GrenonBy Allyson Whyte Nowak and Amy Grenon on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
Case:  Eli Lilly Canada Inc et al v Teva Canada Limited, 2017 FC 88 Drug:  ZYPREXA® (olanzapine) Nature of case: Action pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 (the Regulations) Successful party: Teva Canada Limited Date: April 4, 2017 (public reasons) Summary The Federal Court established the parameters to … Continue reading

Current directions in regulatory and intellectual property law in Canadian pharmaceutical cases

Judith RobinsonJordana SanftBy Judith Robinson and Jordana Sanft on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
Recent pharmaceutical cases in regulatory and intellectual property law have resulted in developments on several fronts, including: regulatory matters; patent validity and damages; Patented Medicines (Notice of Compliance) Regulations proceedings; and class actions. In this paper, we review some of the most notable Canadian decisions from 2015 that will continue to impact the legal landscape … Continue reading

Pharma in brief – TMOB dismisses section 45 proceedings for the trade-mark REMODULIN

Kristin WallBy Kristin Wall on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
Case: Blake, Cassels & Graydon LLP v United Therapeutics Corporation, 2017 TMOB 9 Trade-Mark: REMODULIN Nature of case: Summary expungement proceedingpursuant to section 45 of Trade-marks Act Successful party: United Therapeutics Corporation Date of decision: January 26, 2017 Summary The Trademarks Opposition Board (TMOB) accepted United Therapeutics Corporation’s evidence of use of the trade-mark REMODULIN … Continue reading
LexBlog